The current application status of immunotherapy in solid tumors
10.11904/j.issn.1002-3070.2024.01.009
- VernacularTitle:免疫治疗在实体瘤中的应用现状
- Author:
Lu ZHAO
1
;
Zhengfeng ZHANG
;
Dazhen WANG
;
Liu YANG
;
Ze LIU
;
Changjie LOU
Author Information
1. 哈尔滨医科大学附属肿瘤医院消化内科二病房(哈尔滨 150081)
- Keywords:
Immunotherapy;
Immune checkpoint inhibitors;
Oncolytic virus therapy;
Chimeric antigen receptor T cell therapy
- From:
Practical Oncology Journal
2024;38(1):55-61
- CountryChina
- Language:Chinese
-
Abstract:
Cancer immunotherapy has great potential and is expected to become the mainstream method of cancer treatment.In the current application of cancer immunotherapy,immune checkpoint inhibitors(ICIs)have achieved remarkable results.The cur-rently widely used ICIs in clinical practice include inhibitors targeting cytotoxic T lymphocyte-associated antigen-4(CTLA-4),pro-grammed death-1(PD-1)and programmed death-ligand 1(PD-L1).In addition,new immunotherapies such as oncolytic viruses and chimeric antigen receptor T cells are gradually entering the clinical practice,and combination therapy related to ICIs has shown unique advantages.This article will focus on the current application status of ICIs,oncolytic viruses,and chimeric antigen receptor T cell ther-apies in solid tumors either their individual or combined forms.
